December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.07 +0.56 (+1.18%)
Streaming Delayed Price Updated: 3:38 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
40 41 Next >
News headline image
Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Earnings Scheduled For July 28, 2023 ↗
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion. 
Via Benzinga
News headline image
Sanofi's Earnings Outlook ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Sanofi? ↗
 
Via Benzinga
News headline image
Looking Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
News headline image
2 Biopharma Stocks Making Big Moves Tuesday ↗
Markets looked poised for a pause, but these stocks didn't stand still. 
Via The Motley Fool
News headline image
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports ↗
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss... 
Via Benzinga
News headline image
7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023 ↗
Even some of the top players of the market don’t get the attention they deserve, making these blue-chip stocks compelling. 
Via InvestorPlace
News headline image
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
From Recludix Pharma, Inc.
Via GlobeNewswire
News headline image
2 Best Biotech Stocks to Buy Right Now ↗
These international-based pharmaceutical companies pay market-topping dividends to shareholders. 
Via The Motley Fool
News headline image
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories ↗
Wall Street Journal 
Via Benzinga
News headline image
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants ↗
The FDA approved AstraZeneca Plc (NASDAQ: 
Via Benzinga
News headline image
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in... 
Via Benzinga
News headline image
Is Affordable Insulin Available? Survey Reveals Uninsured Americans Paying More Despite Promised Price Reduction ↗
According to a survey conducted by U.S. 
Via Benzinga
News headline image
Why Shares of Exscientia Jumped on Wednesday ↗
The company may be riding the wave of an AI healthcare boom. 
Via The Motley Fool
News headline image
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
News headline image
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA) ↗
Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its breakt 
Via Benzinga
News headline image
Evotec Secures US Government Contract For Orthopoxvirus Antibody ↗
The U.S. 
Via Benzinga
News headline image
First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California ↗
The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs. 
Via Benzinga
News headline image
Sanofi's Amlitelimab Hits Primary Goal In Mid-Stage Atopic Dermatitis Study ↗
Sanofi SA (NASDAQ: SNY) says its Phase 2b study (STREAM-AD) of amlitelimab for adults with moderate-to-severe atopic dermatitis, who cannot adequately manage their condition with topical medications,... 
Via Benzinga
News headline image
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News ↗
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues. 
Via Investor's Business Daily
News headline image
GSK Confidentially Settles First Zantac-Associated Cancer Lawsuit Due For US Trial Next Month ↗
GSK plc (NYSE: GSK) has reached a confidential settlement with James Goet 
Via Benzinga
News headline image
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide ↗
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i 
Via Benzinga
News headline image
Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
Sanofi Stock Is Trading Higher Today - Here's Why ↗
Sanofi SA (NASDAQ: SNY) announced that the tribunal dismissed Boehringer Ingelheim's indemnification claim against Sanofi in an International Chamber of Commerce dispute in cancer lawsuits linked to... 
Via Benzinga
News headline image
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? ↗
Company Moves Ahead With Drug Development 
Via Benzinga
News headline image
DarioHealth is an AI-Powered Digital Therapeutics Play
DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories ↗
Financial Times 
Via Benzinga
News headline image
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon ↗
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.